Geode Capital Management LLC Has $595,000 Holdings in Mural Oncology plc (NASDAQ:MURA)

Geode Capital Management LLC lifted its stake in shares of Mural Oncology plc (NASDAQ:MURA) by 2.6% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 190,056 shares of the company’s stock after buying an additional 4,731 shares during the period. Geode Capital Management LLC’s holdings in Mural Oncology were worth $595,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of MURA. Rhumbline Advisers purchased a new position in shares of Mural Oncology during the second quarter valued at approximately $34,000. Commerce Bank purchased a new position in shares of Mural Oncology during the third quarter valued at approximately $39,000. FMR LLC boosted its position in shares of Mural Oncology by 124.7% during the third quarter. FMR LLC now owns 20,580 shares of the company’s stock valued at $64,000 after buying an additional 11,423 shares during the last quarter. Canada Pension Plan Investment Board purchased a new position in shares of Mural Oncology during the second quarter valued at approximately $70,000. Finally, Dimensional Fund Advisors LP purchased a new position in shares of Mural Oncology during the second quarter valued at approximately $71,000. Hedge funds and other institutional investors own 80.21% of the company’s stock.

Mural Oncology Price Performance

Shares of MURA opened at $3.89 on Friday. The firm has a market cap of $66.21 million, a PE ratio of -0.43 and a beta of 3.83. The stock’s fifty day moving average price is $3.55 and its two-hundred day moving average price is $3.39. Mural Oncology plc has a 1 year low of $2.87 and a 1 year high of $5.62.

Insider Buying and Selling at Mural Oncology

In other Mural Oncology news, CFO Adam D. Cutler sold 7,421 shares of the business’s stock in a transaction on Thursday, October 31st. The stock was sold at an average price of $3.41, for a total value of $25,305.61. Following the sale, the chief financial officer now directly owns 71,438 shares in the company, valued at $243,603.58. The trade was a 9.41 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 0.06% of the company’s stock.

Wall Street Analysts Forecast Growth

MURA has been the topic of a number of recent analyst reports. Raymond James initiated coverage on Mural Oncology in a report on Friday, October 4th. They set a “strong-buy” rating and a $18.00 price target on the stock. HC Wainwright reiterated a “buy” rating and set a $18.00 price target on shares of Mural Oncology in a report on Monday, November 11th.

Mural Oncology Company Profile

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.